Lymphoma Cell Bank Announced
The Lymphoma Research Foundation (LRF)has just launched the very first Mantle Cell Lymphoma (MCL) Cell Bank, a collection of various MCL cell lines created by scientists from all over the world. It was created to provide a single, centralized location where scientists can easily acquire high-quality, well-characterized MCL cell lines in an effort to accelerate discoveries in MCL. LRF is currently in the process of acquiring 15 different MCL cell lines. As additional cell lines become available they will be added to the Cell Bank.
The Cell Bank is chaired by Dr. Owen O'Connor of Columbia University and is housed at ATCC, the world's largest biological resource center and the most comprehensive source of reference cultures and reagents used by researchers in the academic and industry laboratories. The Cell Bank was made possible by the scientists who generously agreed to share their resources, including, Dr. Elias Campo, Dr. Richard Ford, and Dr. Junia Melo.
While it is not an immediate benefit to patients, it will broaden the number of researchers who can gain access for their studies.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
